BDX vs EW: fair value comparison
Becton, Dickinson and Company and Edwards Lifesciences Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our discount ranking. EW carries the stronger quality grade.
| BDX | EW | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $184.74 | $89.90 |
| 12-month range | $145.33–$201.91 | $81.26–$90.74 |
| Sector rank | #53 of 113 Healthcare | #50 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BDX fair value analysis · EW fair value analysis